ReviewJournal of pharmaceutical sciences2003
Innovations in oligonucleotide drug delivery.
Review in Journal of pharmaceutical sciences, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 86 citations in OpenAlex.
- Gene network changes after exposure to nanoliposomes containing antisense miR-21 and miR-373 in bladder cancer Cells: AnBiochemistry and biophysics reports · 2025Article
- The Progress and Evolving Trends in Nucleic-Acid-Based Therapies.Biomolecules · 2025Review
- A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.Molecules (Basel, Switzerland) · 2024Review
- Advancements in application of chitosan and cyclodextrins in biomedicine and pharmaceutics: recent progress and future trends.RSC advances · 2024Review
- Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Supramolecular nanomedicines based on host-guest interactions of cyclodextrins.Exploration (Beijing, China) · 2023Review
- Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.Pharmaceutics · 2023Review
- Article
- Isolation and Characterization of Engineered Nucleoside Deoxyribosyltransferase with Enhanced Activity Toward 2'-Fluoro-2'-Deoxynucleoside.Journal of microbiology and biotechnology · 2022Article
- Gold Nanoparticles Prepared with Cyclodextrin Applied to Rapid Vertical Flow Technology for the Detection of Brucellosis.Biosensors · 2022Article
- A perspective on oligonucleotide therapy: Approaches to patient customization.Frontiers in pharmacology · 2022Review
- Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes.PloS one · 2017Article
- Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.International journal of nanomedicine · 2015Article
- Modulation of polyplex release from biodegradable microparticles through poly(ethylenimine) modification and varying loading concentration.Pharmaceutical research · 2014Article
- Diseases originate and terminate by genes: unraveling nonviral gene delivery.Drug delivery and translational research · 2013Article
- Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.Advanced drug delivery reviews · 2013Review
- Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.The EPMA journal · 2010Article
- Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability.Small (Weinheim an der Bergstrasse, Germany) · 2009Article
- Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Gene regulation and systems biology · 2008Article
- Glycotargeting to improve cellular delivery efficiency of nucleic acids.Glycoconjugate journal · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligonucleotides (ONs) are a new class of therapeutic compounds under investigation for the treatment of a variety of disease states, such as cancer and HIV, and for FDA approval of an anti-CMV retinitis antisense molecule (Vitravene trade mark, Isis Pharmaceuticals). However, these molecules are limited not only by poor cellular uptake, but also by a general lack of understanding regarding the mechanism(s) of ON cellular uptake. As a result, various delivery vehicles have been developed that circumvent the proposed mechanism of uptake, endocytosis, while improving target specific delivery and/or drug stability. This review describes various traditional and novel delivery mechanisms that have been employed to improve ON cellular delivery, cost effectiveness, and therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.